RAS LSS Consulting’s Post

#Smallmolecules represent the next frontier of immuno-oncology and such drugs now entering the clinical research stage. #Kumquat has been on the forefront with its first small-molecule #immunooncology partnership with #EliLilly in July 2021. Takeda's #oncologypipeline consists primarily of small molecules which means that there are several combination opportunities that could be explored with Kumquat`s molecule. Between Takeda and Eli Lilly, Kumquat stands to make ~$3.2B in future development, regulatory and commercial milestones. #innovation #oncology

Exciting times in the world of immuno-oncology! 🎉 Kumquat Biosciences and Takeda join forces in a groundbreaking pact with over $1.2 billion at stake. 🤝🔬 This alliance brings together a pioneering biotech and a pharmaceutical giant, spotlighting a promising small molecule inhibitor. As Kumquat completes phase 1 trials, Takeda stands ready to propel development and commercialization to new heights. 💡 The potential here is immense - not just in financial terms with up to $130 million in near-term payments for Kumquat, but in the true value that such medical advancements can bring to cancer treatment. 🌟 A testament to strategic collaborations, this partnership reiterates our collective commitment to innovation in the battle against cancer. 🔍💊 #ImmunoOncology #PharmaPartnerships #Innovation #Takeda #KumquatBiosciences

We are very excited to introduce Iteria Biopharma, a new #biotech focused on the discovery of precision drugs for #cancer treatment. We are launching this new company with our partners Julio Castro-Palomino, CEO and cofounder of Palobiofarma S.L., and Ramon Bosser as CEO, who also led our previous spin-off Origo Biopharma (later on acquired by Agomab ). 𝗜𝘁𝗲𝗿𝗶𝗮 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 will apply the latest advances in the design of new compounds to already validated therapeutic targets that are however extremely complicated to modulate using conventional #drugdiscovery methods. The new Galician company begins its journey with the preclinical development of a #candidate for the treatment of #prostate cancer resistant to androgen deprivation therapy, taking over from the advances achieved by GalChimia in the project #MAOPROST (R&D program CPP2021 by Ministry of Science and Innovation of Spain). #passionforchemistry #biotechnology #Galicia #innovation #techtransfer #oncology https://lnkd.in/dDbmxuWD

🔬 Nimbus Therapeutics Secures $210M in Strategic Funding TL;DR: • $210M raised, led by GV • Follows $4B Takeda deal • Advancing HPK1 inhibitor in Phase 1/2 • Unique LLC model continues to deliver results Nimbus Therapeutics is entering its "third chapter" with a substantial $210M financing round, building on momentum from their recent $4B Takeda deal. The funding, led by GV with support from Atlas Venture and SR One, will accelerate development of their innovative cancer and metabolic disease pipeline. At the forefront is NDI-101150, their HPK1-targeting molecule in Phase 1/2 trials for solid tumors. This program exemplifies Nimbus's commitment to developing standalone cancer immunotherapies that address the industry's combination therapy challenges. The company's unique LLC structure, established during the 2009 recession, continues to prove successful. This model enables individual program development within subsidiaries, facilitating strategic exits while maintaining private ownership. What's next for Nimbus? • Phase 1/2 trial results expected next year • Advancing preclinical programs • Expanding collaborations, including Eli Lilly partnership • Continuing private development strategy 💭 What are your thoughts on Nimbus's private development approach versus the traditional IPO route? Share your insights below. #Biotech #DrugDevelopment #CancerResearch #BiotechNews #Innovation #intelligencesimplified #pharma #biotech #biodatastudio

𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 𝐄𝐱𝐩𝐚𝐧𝐝𝐬 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐰𝐢𝐭𝐡 𝐃𝐫𝐞𝐧 𝐁𝐢𝐨 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 Novartis Novartis has entered a strategic collaboration with Dren Bio Dren Bio, Inc. to develop bispecific antibodies for cancer. This includes a $150 million upfront payment, $25 million equity investment, and up to $2.85 billion in potential milestones. Dren Bio’s platform targets myeloid cells to enhance therapeutic effects and safety. Novartis will handle clinical development, manufacturing, regulatory, and commercialization activities. This partnership adds to Novartis’ recent deals, including acquisitions of Mariana Oncology and a partnership with PeptiDream. #Novartis #Oncology #CancerTreatment #BispecificAntibodies #Biotech #Pharma #ImmunoOncology #ClinicalDevelopment #HealthcareInnovation #DrenBio #Partnerships

competitive market is on the way!!

💉 𝗟𝗲𝘁’𝘀 𝗻𝗼𝘁 𝘀𝘁𝗿𝗮𝘆 𝘁𝗼𝗼 𝗳𝗮𝗿 𝗳𝗿𝗼𝗺 𝗞𝗲𝘆𝘁𝗿𝘂𝗱𝗮! 🧬 🟢 In the previous post, we discussed #Keytruda’s development history, its approved indications, and its increasing sales year by year after hitting the market. We also took a peek into Merck’s efforts to extend Keytruda’s exclusivity by filing numerous patents around this valuable blockbuster! 🟢 Pembrolizumab, the active ingredient in Keytruda, is a powerhouse in the PD-1 inhibitor class of cancer treatments. PD-1, or programmed cell death-1 receptor, is crucial to the body’s immune response. By blocking the interaction between PD-1 and its ligand PD-L1, pembrolizumab empowers the immune system to better recognize and destroy tumor cells. 🟢 With Keytruda’s patent expiration still four years away, biosimilar makers are gearing up for a major opportunity. Developing biosimilars can significantly benefit patients by providing more affordable treatment options, offering the same effectiveness as the original biologic drugs at a lower cost, thereby improving access to life-saving medications. 🟢 While it’s too early to predict who will bring the first pembrolizumab biosimilar to market, several major developers are making significant strides. Companies like Samsung Bioepis, Sandoz, Amgen, Bio-Thera Solutions, and mAbxience have promising candidates in the clinical trial studies, while Formycon AG, Alvotech, Henlius, and NeuClone have Keytruda's biosimilars on their preclinical pipeline. Moreover, Xbrane Biopharma AB had indicated an interest in its pembrolizumab biosimilar candidate but announced in November 2023 that it was terminating development. 🟢 𝗪𝗲 𝗦𝘁𝗮𝘆 𝗧𝘂𝗻𝗲𝗱 as these developments unfold, potentially reshaping cancer therapy with new and more affordable treatment options. The competition is heating up, and the outcome could transform the landscape of #oncology! #biosimilar #biopharma #pharmaceuticalindustry #blockbuster #clinicaltrial #pembrolizumab

Big Pharma is on the hunt for quality targets. Oncology is an area of interest. "The global oncology market was worth USD 203.42bn in 2022 and is projected to soar to more than USD 470.61bn by 2032, according to a report by Precedence Research." "MorphoSys, a German biotech company founded in 1992, has led the way by participating in some of the largest deals involving biotech companies in oncology in EMEA in recent years, according to Mergermarket data." To learn more about current oncology landscape in Europe and potential assets expected to come to the market click below. #mergersandacquisitions #bigpharma #oncology #foundingrounds #antibodydrugconjugates #ADCs #biotech #trends2024

A GlobalData report shows a total of 500 companies - ranging from established industry leaders to niche startups - that are actively engaged in the development and application of antibody-drug conjugates. Some excellent market insights in this article. #ADC #oncology #pharma #ONFAB

ProfoundBio secured $112 million to advance their promising ADC pipeline, including Phase II candidate Rina-S for ovarian cancer. This boost positions them well in the booming ADC market, fueled by recent investments from major pharma players such as: • Eli Lilly and Company: In January 2024, Lilly acquired Akari Therapeutics, Plc for $5.4 billion, gaining access to their ADC candidate for HER2-positive breast cancer. • Pfizer: In February 2023, Pfizer offered $43 billion to acquire Seagen, a leader in ADC development with several approved products. • GSK: In December 2023, GSK partnered Jiangsu Hansoh Pharmaceutical Group Co., Ltd. in a $270 million deal for commercialization and co-development rights to two ADCs. • AbbVie: In January 2024, AbbVie partnered with Genmab for $500 million, gaining rights to develop and commercialize an ADC for B-cell malignancies. #investment #funding #adctherapy #growth #biotechstartup #pharmaceuticalindustry